What to expect when Cochlear (ASX:COH) releases its half year results

What should you expect from Cochlear?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Cochlear is releasing its half year results next week
  • The hearings solutions company has provided not first half guidance but is expecting full year profit growth of 12% to 20% 
  • The market consensus is for modest first half profit growth

The Cochlear Limited (ASX: COH) share price will be one to watch next week.

On 22 February, the hearing solutions company is scheduled to release its half year results.

Ahead of the release, let's take a look to see what the market is expecting from Cochlear.

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices

Image source: Getty Images

What should you expect from Cochlear?

The market is expecting a mildly positive half year result from Cochlear next week. According to a note out of Citi, the market consensus estimate is for a net profit of $127.6 million.

This is up marginally on the prior corresponding period when the company reported a net profit of $125.3 million.

However, Citi is expecting Cochlear to outperform the market's expectations. It is forecasting a first half net profit of $140.9 million, representing growth of 12.5% over the prior corresponding period.

If Cochlear were to achieve Citi's estimate, it would mean it is on course to deliver on its guidance in FY 2022. At its annual general meeting, management reaffirmed its FY 2022 guidance for underlying net profit growth of between 12% and 20%.

Management advised that this is expected to be underpinned by market growth, with a continuing recovery in surgery rates across many countries more affected by COVID.

What are others saying?

While it hasn't provided a first half estimate, the team at Goldman Sachs expects a full year result in August ahead of guidance.

It commented: "We forecast $288m NPAT (17.7% margin) in FY22, which remains above COH guidance of $265-285m."

Though, the broker has warned that while COVID headwinds are easing, "it is possible there is some persistent hesitancy amongst a proportion of its target market in DMs (aged 70+)." Therefore, investors may want to listen out for any commentary on that front.

All in all, the result could be one of the more interesting ones this season.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A cool white-bearded man holds his hand up signalling you should halt.
Healthcare Shares

ASX 300 cannabis stock Incannex suspended ahead of 'material update'

The Incannex share price is frozen at 14 cents for now.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX All Ords stock is rocketing 27% on a new FDA approval

Rett Syndrome has finally got an approved treatment.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Buy these excellent ASX 200 healthcare shares: Goldman Sachs

Goldman has spoken very positively about these healthcare shares this week.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Guess which ASX biotech stock just rocketed 29% on big FDA news

The ASX healthcare share is attracting investor interest following FDA approval for its targeted cancer therapy compound.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares while they're under $300?

Can investors make a healthy return with this biotech?

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Mesoblast share price rockets 23% on FDA news

Mesoblast has received some good news for the US FDA this morning.

Read more »

A young woman wearing a blue blouse with white polkadots holds her phone up with an intrigued and happy look on her face as she reads some news.
Healthcare Shares

Owners of this ASX 200 share are soon going to receive a bigger dividend

Investors in this healthcare company are about to get a healthy cash boost.

Read more »

an older couple look happy as they sit at a laptop computer in their home.
Healthcare Shares

Hoping to collect the latest CSL dividend? Here's how

The next CSL dividend is fast approaching.

Read more »